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ABSTRACT
While high doses of estrogen, in combination with androgens, can initiate 
prostate cancer (PCa) via activation of the estrogen receptor α (ERα), the role of 
ERα in PCa cells within established tumors is largely unknown. Here we show that 
expression of ERα is increased in high grade human PCa. Similarly, ERα is elevated 
in mouse models of aggressive PCa driven by MYC overexpression or deletion of 
PTEN. Within the prostate of PTEN-deficient mice, there is a progressive pattern of 
ERα expression: low in benign glands, moderate in tumors within the dorsal, lateral 
and ventral lobes, and high in tumors within the anterior prostate. This expression 
significantly correlates with the proliferation marker Ki67. Furthermore, in vitro 
knockdown of ERα in cells derived from PTEN-deficient tumors causes a significant 
and sustained decrease in proliferation. Depletion of ERα also reduces the activity 
of the PI3K and MAPK pathways, both downstream targets of non-genomic ERα 
action. Finally, ERα knockdown reduces the levels of the MYC protein and lowers 
the sensitivity of cellular proliferation to glucose withdrawal, which correlates with 
decreased expression of the glucose transporter GLUT1. Collectively, these results 
demonstrate that ERα orchestrates proliferation and metabolism to promote the 
neoplastic growth of PCa cells.
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INTRODUCTION
Prostate cancer is the second leading cause of 
cancer-related death in US men; 1 in 7 men will be 
diagnosed in their lifetime and 1 in 37 will die from 
prostate cancer [1]. Androgens are the main regulators 
of prostatic cell proliferation in development and 
homeostasis. Androgens and the androgen receptor (AR) 
also drive the progression of prostate cancer, although 
the disease is often diagnosed at an age when the serum 
level of testosterone in men is declining [2]. Nevertheless, 
prostate cancer is an endocrine-related cancer where 
androgens are necessary, but insufficient, to cause cancer 
development and progression [3]. Yet, combined treatment 
of mice or benign human xenografts with high levels of 
testosterone and estradiol induces prostate carcinogenesis 
[4, 5]. This demonstrates that along with androgens, 
estrogens have a critical role in prostate cancer.
Estrogens regulate proliferation and cell death 
in the prostate and have dual roles in prostate cancer, 
either pro- or anti-tumorigenic. These specific actions 
are mediated by the two estrogen receptor (ER) subtypes, 
ERα or ERβ [6]. The anti-tumorigenic role of ERβ has 
been studied in detail [7]. Specific activation of ERβ 
with selective agonists causes apoptosis, decreases tumor 
growth in vivo and inhibits epithelial-to-mesenchymal 
transition [8-10]. The pro-tumorigenic actions of ERα 
are comparatively ill-defined. One explanation for the 
paucity of research into ERα in prostate cancer is the 
uncertainty about its expression profile; ERα is abundantly 
expressed in normal and tumor stroma, but there are 
differing reports about whether it is expressed in epithelial 
prostate cancer cells [11-17]. Most studies have detected 
negligible ERα staining in prostate cancer cells using 
immunohistochemistry. This could be due to an under-
representation of high grade samples because other studies 
showed that ERα expression in prostate cancer cells is 
significantly associated with high Gleason score and poor 
patient survival [11, 17]. A second reason that the role of 
ERα in prostate cancer cells has been underestimated, is 
that most human prostate cancer cell lines express little 
or no ERα [18-22]. Therefore, the goal of this study 
was to resolve the expression profile of ERα in prostate 
cancer cells and identify new models to study its effects. 
By focusing on the autonomous role of ERα in prostate 
cancer cells, including interactions with other signalling 
pathways, we aimed to provide a more comprehensive 
understanding of estrogen action in prostate cancer.
The role of ERα in cancer cell proliferation and 
survival has been extensively studied in the breast and 
other female tissues such as the ovary, uterus and cervix. 
These studies demonstrate that ERα is a multifunctional 
protein; in addition to its genomic role as a transcription 
factor, where agonist-bound ERα regulates the expression 
of downstream genes containing estrogen-response 
elements (ERE) [23], ERα localizes to the cell membrane 
via palmitoylation to direct “non-genomic” activities [24]. 
At the plasma membrane, ERα interacts with c-Src and the 
regulatory subunit of PI3K, p85α, to augment signaling 
activity through the MAPK and PI3K pathways [25-27], 
both drivers of growth, proliferation and survival.
The interaction of ERα and survival signaling 
cascades is potentially significant because they are 
commonly dysregulated in prostate cancer. The PTEN 
tumor suppressor is frequently lost through single or bi-
allelic deletion, mutations and epigenetic silencing [28, 
29]. PTEN insufficiency promotes hyperactivation of the 
kinase AKT, leading to pro-survival and pro-proliferative 
signaling. Moreover, loss of PTEN synergizes with loss 
of p53, over-expression of MYC and sustained activation 
of MAPK in promoting prostate cancer initiation 
and progression [30-32]. In our studies of mice with 
conditional PTEN knockout in the prostate epithelium 
(PBiCre+/-;Ptenfl/fl), we noted a marked up-regulation of 
ERα expression during cancer progression. This led us 
to investigate estrogen signaling in the PTEN-deficient 
model.
Here we show, in the PTEN-deficient model of 
prostate cancer, that the expression of ERα (but not AR 
or ERβ) is significantly increased in regions of tumors 
where cell proliferation is notably enhanced. In addition, 
in human prostate cancer specimens we demonstrate that 
ERα expression is associated with regions of high Gleason 
score, indicative of more aggressive disease. Stable down-
regulation of ERα expression in cell lines derived from 
primary PTEN-deficient tumors induced a striking and 
sustained reduction in proliferation. Our results indicate 
that ERα promotes the proliferation in PTEN-deficient 
tumors by regulating MYC expression and glucose 
sensitivity.
RESULTS 
ERα is expressed in prostate cancer cells
It is contentious whether ERα is expressed in 
prostate cancer cells or only the stroma [11-13, 17, 22]. 
This prompted us to re-examine ERα expression in 
prostate cancer using immunohistochemistry. It has been 
suggested that ERα is up-regulated in high grade disease 
[11], so we selected a cohort of Gleason score 9 specimens 
and a similar number of low grade Gleason score 6 
tumors for comparison. As expected, AR was abundantly 
expressed in the epithelium in all samples (Supplementary 
Fig. 1 and Supplementary Table 1). ERα was expressed in 
48% (10/21) of Gleason score 9 tumors, but no Gleason 
score 6 tumors (0/15), consistent with a previous study 
(Fig. 1A and B) [11]. This increase in ERα expression 
in high grade human prostate cancer was statistically 
significant (P=0.001). In the positive specimens, 10-80% 
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(average 40%) of all cancer cells exhibited prominent 
nuclear staining of ERα (Supplementary Table 1). These 
findings warranted further studies into the biological 
significance of ERα in prostate cancer. Most human 
epithelial prostate cancer cell lines, however, express little 
or no ERα, so are inappropriate to study the autonomous 
role of ERα [18-22]. To identify systems to study the 
biological significance of ERα, we therefore examined 
ERα expression in mouse models of aggressive prostate 
cancer. Consistent with data from our human specimens, 
ERα levels are increased in tumors from both Hi-MYC 
(Fig. 1D) and PTEN-deficient (Fig. 1F) mice when 
compared to normal prostate tissue from control mice 
(Fig. 1C and E). Collectively, these data show that ERα 
is expressed in epithelial cells in a subset of aggressive 
prostate cancers and indicate that a number of mouse 
models mirror this expression pattern. 
ERα expression correlates with Ki67 in PTEN-
deficient murine prostate cancer
Further analysis of ERα immunoreactivity 
in the prostates of PTEN-deficient mice revealed 
particularly intense staining towards the periphery of 
the malignant foci. This resembled the band of Ki67-
positive proliferating cells that has previously been 
reported [33] and prompted us to investigate whether 
ERα and Ki67 levels correlate. To test this, staining 
was quantified in serial sections from four different 
zones of the prostate that have distinctive patterns of 
Ki67 expression (Supplementary Fig. 2A). The highest 
percentage of Ki67 and ERα positive cells was in the 
peripheral region of anterior prostate (AP) tumors (Fig. 
2A). In contrast, ERβ and AR staining did not vary across 
Figure 2: ERα expression correlates with proliferation 
in PTEN-deficient prostate cancer. (A) Representative 
images of immunohistochemical staining of Ki67, ERα, ERβ and 
AR in the anterior prostate of 12-14 week old PTEN-deficient 
mice. The peripheral and central regions of the foci are shown 
in the Ki67 image. Scale bars = 50 µm. (B) Dot plot comparing 
the percentage of ERα and Ki67 positive cells in the prostate 
of PTEN-deficient mice (P<0.001, r2=0.75, Pearson correlation, 
n=12 regions from 3 mice).
Figure 1: ERα expression increases in prostate 
cancer. Representative images of ERα staining in human 
and mouse prostate cancer. Specimens of (A) Gleason score 
6 and (B) Gleason score 9 human prostate cancer. (C) Benign 
lateral prostate tissue of a 5 month old control mouse (FVB) 
compared to (D) prostate cancer in an age-matched Hi-MYC 
mouse (ARR2/Pbsn-Myc). (E) Benign anterior prostate tissue 
from a 80-100 day old control mouse (PBiCre+/-) compared to 
(F) malignant tissue in an age-matched PTEN-deficient animal 
(PBiCre+/-;Ptenfl/fl). Scale bars equal 50 µm. 
Oncotarget607www.impactjournals.com/oncotarget
different regions (Fig. 2A and Supplementary Fig. 2B). 
Moreover, there were moderate levels of Ki67 and ERα 
staining in the central region of AP tumors and in tumors 
in the dorsal, lateral and ventral prostate (DLVP), but few 
cells stained in benign areas of the DLVP (Fig. 2A and 
Supplementary Fig. 2B). Both the differences in Ki67 and 
ERα positive cells between regions (Supplementary Fig. 
2C and 2D) and the correlation between the proportion of 
Ki67 and ERα stained cells within the prostates of PTEN-
deficient mice (Fig. 2B) were statistically significant. The 
strong correlation between ERα and Ki67 staining implied 
that ERα may regulate the proliferation of prostate cancer 
cells.
ERα regulates proliferation
We investigated whether ERα regulates proliferation 
using prostate cancer cells derived from the prostate of 
PTEN-deficient mice. These cells are epithelial, based 
on the expression of epithelial rather than stromal 
phenotypic markers (Supplementary Fig. 3A and 3B). 
They also maintain AR expression (Supplementary Fig. 
4A). Immunoblots confirmed that the PTEN-deficient cells 
also express abundant levels of full length ERα (ERα66) 
(Fig. 3A, lane 1) like MCF7 breast carcinoma cells, which 
were used as a positive control (Fig. 3A, lane 4). Treating 
the PTEN-deficient cells for 5 days with 1 µM of TPSF, a 
non-competitive antagonist of ERα, reduced proliferation 
by ~25% (Fig. 3B), similar to its effect on MCF7 cells 
[34]. There was no change in cell viability, showing that 
TPSF did not induce apoptosis (Supplementary Fig. 5). To 
confirm this finding, we also established PTEN-deficient 
cell lines stably expressing a non-targeting shRNA (shCtl) 
or an ERα-specific shRNA (shERα). The shCtl cells 
expressed a similar amount of ERα compared to parental 
PTEN-deficient cells, while the shERα cells had a ~70% 
reduction in the amount of ERα (Fig. 3A, lane 2 and 3 
and Supplementary Fig. 4B). We then compared the 
Figure 3: ERα knockdown inhibits the growth of PTEN-deficient prostate cancer cells. (A) Representative Western blots of 
ERα, PTEN and pan-actin levels in parental (untransfected) PTEN-deficient prostate cancer cells and cells stably expressing non-silencing 
shRNA control (shCtl) or ERα shRNA (shERα). MCF7 cells were used as a control for ERα and PTEN expression. (B) Relative percentage 
of cells after 5 days of treatment with DMSO or 1 μM TPSF (*P<0.05, paired T Test, n=3). (C) Average number of shCtl and shERα cells 
after 1, 3 and 5 days of culture (**P<0.01, ***P < 0.001, 2 Way ANOVA, n=3). (D) Average percentage of cells relative to the shCtl over 
5 passages (**P<0.01, ****P<0.0001, n=3 flasks, two way ANOVA). Average number (E) and diameter (F) of colonies formed in Matrigel 
(***P<0.0001, t test, n=10 wells). (G) Representative phase contrast images of colonies formed by shCtl and shERα knockout cells. Scale 
bars = 100 µm. Data for shCtl is shown in white and data for shERα is shown in grey.
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proliferation of shCtrl cells with shERα cells. Consistent 
with the effect of 1 µM TPSF treatment, ERα knockdown 
led to a 27% decrease in the number of cells over 5 days 
(Fig. 3C). Strikingly, the impact of lowering the amount of 
ERα in PTEN-deficient cells lead to a sustained reduction 
in the proliferation, demonstrated by a 76.5% decrease 
in the number of shERα cells compared to shCtrl cells 
over 5 passages (Fig. 3D). Once again, there was no 
difference in the cell viability (Supplementary Fig. 5). 
PTEN-deficient cells form colonies in Matrigel [35]; the 
ability of individual cells to form colonies is a measure of 
clonogenicity, whereas the size of each colony indicates 
their proliferative potential. Depletion of ERα did not 
change the number of colonies (Fig. 3E), but it led to a 
significant decrease in the size of the colonies (Fig. 3F 
and G). This confirms that ERα regulates proliferation of 
prostate cancer cells. 
ERα sustains PI3K and MAPK signaling
Since ERα stimulates PI3K and MAPK signaling, 
we hypothesized that the decrease in proliferation upon 
depletion of ERα was due to attenuated activity through 
these pathways. Therefore, we tested the phosphorylation 
status of key proteins in extracts from shCtrl cells, shERα 
cells and, to confirm that any changes in phosphorylation 
were dependent on ERα expression, shERα cells rescued 
by transfection with a shRNA-resistant ERα construct. 
The phosphorylation of AKT (mTORC2 site S473) and 
S6K (mTORC1 site T389), which are key proteins in 
the PI3K pathway, was reduced by ERα knockdown, 
demonstrating attenuated activity downstream of PI3K 
(Fig. 4). MAPK activity, assessed by phosphorylation 
of ERK1/2, MNK1 and eIF4E, was also dramatically 
inhibited by ERα depletion, as indicated by a substantial 
decrease in pERK1/2 and pMNK1 levels (Fig. 4). MYC 
is a critical regulator of cell proliferation and survival 
and its expression is regulated downstream of the PI3K 
and MAPK pathways which converge on eIF4E [36]. 
Accordingly, a decrease in MYC protein levels was 
observed in shERα cells (Fig. 4). Re-expression of ERα 
rescued PI3K and MAPK activity and restored MYC 
expression to the levels detected in shCtrl cells, confirming 
the specific action of ERα. These data demonstrate 
that ERα sustains the activity of the PI3K and MAPK 
pathways in prostate cancer cells.
ERα transcriptome is enriched in metabolic genes
The ERα transcriptome varies between cell types 
and tissues [37]. As little is known about the transcriptional 
effects of ERα in prostate epithelial cells, we used DNA 
microarrays to compare the mRNA abundance in shCtl 
and shERα cells. Analyses revealed that 1254 genes were 
up-regulated and 1078 were down-regulated following 
depletion of ERα (fold-change >1.5 and False Discovery 
Rate [FDR]<0.1). To assess the functional impact of 
these vast changes in steady state mRNA levels, we used 
a gene set enrichment approach to identify prominent 
functions among differentially regulated genes. Following 
filtering (FDR<0.15), 5 pathways, all involved in cell 
division, were up-regulated in shERα versus shCtl cells 
(Supplementary Fig. 6). In contrast to the relatively few 
pathways identified among genes that are up-regulated 
in shERa cells, 51 pathways were enriched among 
those genes that were down-regulated. Notably, there 
was an overwhelming abundance of genes involved in 
carbohydrate metabolism (Table 1), suggesting that ERα 
modulates such processes either directly or indirectly.
Figure 4: ERα regulates the activity of PI3K and MAPK 
signaling. Representative Western blots of components of 
the PI3K and MAPK signaling pathways in ERα knockdown 
(shERα) and control (shCtl) PTEN-deficient cells. The shERα 
cells were also transfected with an empty vector (+ vector) or 
full length ERα construct (+ ERα) for 3 days. 
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ERα mediates sensitivity to glucose availability
PTEN loss has been linked to resistance to caloric 
restriction in vivo [38] and increased glycolysis in vitro 
[39]. In addition, ERα stimulates glucose metabolism in 
breast cancer cells [40]. Therefore, we tested the impact 
of altering glucose concentration on the proliferation of 
shERα cells compared to shCtrl cells. The proliferation 
of shCtrl cells over three days in the absence of glucose 
was nearly halved (45.4% decrease) compared to shCtrl 
cells grown in high glucose medium (Fig. 5A). In contrast, 
shERα cells were relatively less affected by the absence 
of glucose, displaying a 27.2% decrease in proliferation 
compared to shERα cells grown in high glucose medium. 
This difference in response to glucose withdrawal (P<0.05) 
demonstrates that shCtrl cells are more dependent on 
glucose availability for proliferation compared to shERα 
cells, presenting a potential mechanism whereby ERα 
over-expression may facilitate advanced prostate cancer 
growth. It is noteworthy that glucose deprivation led to 
a reduction in ERα mRNA compared to normal glucose 
conditions; however, the relative levels of ERα in shCtl 
versus shERα cells were maintained with a 70-80% 
decrease in shERα cells (Fig. 5B). 
Recently, a high throughput screen identified 
metabolic enzymes and small molecule transporters that 
confer glucose sensitivity to cancer cells grown in high 
Figure 5: ERα mediates sensitivity to glucose availability. (A) Relative number of cells in shCtl (white) and shERα (grey) cells 
cultured in glucose-free media for 3 days. Data represents relative numbers of cells compared to media with glucose, represented by the 
dotted line (n=3, *P<0.05, T test). (B-G) Relative gene expression in shCtl (white) and shERα (grey) cells in cultured in basal (+glu) 
or glucose-free media for 3 days. Data represent relative gene expression normalized to shCtl cells in basal media (n=3, aFDR<0.05, 
bFDR<0.01 for effect of shRNA; *FDR<0.05, **FDR<0.01, 1 way post-test for the effect of glucose on each shRNA).
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or low glucose concentrations [41]. The factors giving 
a proliferative advantage in high glucose concentration 
were predominantly glycolytic enzymes. Therefore, 
we examined the relative expression of key enzymes 
catalyzing the three irreversible steps of glycolysis 
in shCtl and shERα cells (Fig. 5C-G). There was no 
significant difference in the expression of hexokinase 
2 (Hk2), phosphofructokinase l (Pfkl) and m (Pfkm), or 
pyruvate kinase isoforms (Pkm1, Pkm2) between shCtrl 
and shERα cells grown in high glucose. After glucose 
deprivation, the relative expression of Pfkl, Pfkm and Pkm 
isoforms was reduced (Fig. 5D-G), whereas the expression 
of Hk2 was increased 4-fold in both shCtrl and shERα 
cells, suggesting the cells are compensating by increasing 
hexose phosphorylation activity. 
In contrast to the glycolytic enzymes, the glucose 
transporter Glut1 (Slc2a1) was differentially regulated 
between shCtrl and shERα cells, consistent with the 
microarray analysis. Glut1 was significantly up-regulated 
in shERα cells deprived of glucose (Fig. 5H), but 
unchanged in shCtrl cells. Since GLUT1 is the only small 
molecule transporter demonstrated to affect proliferation 
of cancer cells in low glucose [41], this striking difference 
in the regulation of Glut1 upon glucose deprivation could 
explain the lesser impact of glucose withdrawal on the 
proliferation of shERα cells. Collectively, these data show 
that ERα affects the sensitivity of prostate cancer cells to 
glucose withdrawal.
DISCUSSION
The autonomous role of ERα in prostate cancer 
progression has largely been overlooked. This is due, in 
part, to confusion about the expression of ERα in prostate 
cancer. Previous immunohistochemistry studies reported 
differing levels of ERα in human prostate cancer cells [11-
17], possibly due to differences in the range of Gleason 
score tumors that were examined. We selected a cohort of 
Gleason score 6 and 9 tumors to ensure that low and high 
grade tumors were both represented. ERα was expressed 
in 48% of Gleason score 9 specimens, similar to an early 
study that detected ERα in 43-61% of Gleason grade 4-5 
samples [11]. Another recent study reported that 15% of 
locally invasive tumours, spanning Gleason score 6 to 10, 
expressed ERα and that it was significantly associated 
with biochemical recurrence, decreased progression free 
survival and poor overall survival [17]. In this study, we 
also showed that ERα is highly expressed in two different 
mouse models of aggressive prostate cancer, PTEN-
deficient and Hi-MYC mice, mirroring human disease. 
Together with the estrogenic gene expression signature 
reported by others [22], this confirms that ERα is indeed 
expressed in a subset of high grade prostate cancer. 
It has long been difficult to study the autonomous 
actions of ERα in prostate cancer cells because of a paucity 
of experimental models. Fortunately, our data reveals that 
ERα is expressed in mouse PTEN-deficient prostate cancer 
cells both in vivo and in vitro, making it a suitable model 
to study the role of ERα during prostate tumorigenesis and 
progression. Most human cell lines in contrast, express 
Table 1: Down-regulated gene categories in shERα cells related to small 
molecule metabolism
p.val q.val Cellular functions
7.95E-06 0.010 cellular amino acid metabolic process
1.22E-05 0.011 mitochondrial inner membrane
2.29E-05 0.015 small molecule biosynthetic process
5.37E-05 0.029 carbon-carbon lyase activity
0.000324 0.081 sterol biosynthetic process
0.000351 0.081 deoxyribonucleotide catabolic process
0.000423 0.095 glycosaminoglycan biosynthetic process
0.000462 0.099 chondroitin sulfate biosynthetic process
0.000477 0.099 glycosaminoglycan metabolic process
0.000546 0.110 coenzyme metabolic process
0.000588 0.114 deoxyribose phosphate catabolic process
0.000653 0.116 single-organism carbohydrate catabolic process
0.000690 0.116 cofactor metabolic process
0.000691 0.116 hexose catabolic process
0.000778 0.120 NADP metabolic process
0.000787 0.120 proteoglycan biosynthetic process
0.000872 0.125 monosaccharide catabolic process
0.000978 0.128 generation of precursor metabolites and energy
0.001112 0.134 carbohydrate catabolic process
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little or no ERα, just as some lack the AR. NCI-H660 cells 
and some batches of PC3 cells express ERα [18-22], but 
are not ideal models because they lack AR and have a 
small cell rather than adenocarcinoma phenotype [42, 43]. 
Therefore, identifying new ERα human prostate cancer 
cell lines is a priority. Nevertheless, the ERα negative 
human prostate cancer cell lines have been useful in 
studying the mechanisms underlying ERα expression. The 
lack of ERα expression is due to hypermethylation of the 
ESR1 gene, rather than mutation or deletion [19-21]. This 
suggests that differential methylation could also underlie 
the re-activation of ERα expression in high grade human 
prostate cancer tissue. Since tumours with TMPRSS2-ERG 
fusions have an estrogen-regulated gene signature, it is 
also possible that re-activation of ERα expression is more 
common in this subset of tumours [22]. 
Prostate cancer is often considered to be slow 
growing and to have a low proliferative index, compared to 
other types of tumors. This is true of most cases of low to 
moderate grade disease, but a subset of high grade tumors 
are highly proliferative. Indeed, the percentage of Ki67 
positive cells is a powerful prognostic indicator of poor 
clinical outcome [44]. The significant correlation between 
Ki67 and ERα staining in PTEN-deficient mice links ERα 
to rapidly proliferating, aggressive tumors. Importantly, 
ERα not only correlated with proliferation, it regulated 
the proliferation of PTEN-deficient prostate cancer cells. 
This is consistent with a previous study showing that an 
ERα agonist stimulates the proliferation of a small cell 
prostate cancer cell line, NCI-H660 [22]. Unexpectedly, 
even though ERα knockdown reduces the proliferation 
of PTEN-deficient cells, gene-set enrichment analyses 
showed that some pathways involved in the M phase 
were up-regulated. This may represent a compensatory 
response, albeit insufficient, to the overall decrease in 
proliferation. Nevertheless, since ERα promotes the 
proliferation of prostate cancer cells, specifically inhibiting 
ERα activity could be used to attenuate the growth of a 
subset of aggressive tumors. 
Loss of PTEN is associated with progression to 
the most aggressive stages of prostate cancer [45]. Initial 
loss of one allele can be followed by complete lack of 
expression [29]. Loss of PTEN synergizes with loss of 
p53, overexpression of MYC and sustained activation 
of MAPK in promoting prostate cancer initiation and 
progression [30-32]. Our results demonstrate that ERα can 
regulate MYC expression upstream of the MAPK pathway. 
Considering that activating mutations in the RAS/RAF/
MEK/ERK signaling cascade are rare in prostate cancer 
[46, 47], sustained stimulation of the MAPK pathway by 
ERα is a potential mechanism to increase MYC expression 
in a subset of prostate cancers.
ERα affects glucose metabolism in human breast 
cancer cells [40] and our data demonstrate that the same 
is true in mouse PTEN-deficient prostate cancer cells. 
Indeed, ERα knockdown decreased the expression of 
Glut1 (SLC2A1). Highly proliferative PTEN-deficient 
tumour cells are often sensitive to decreases in glucose 
levels because they exhibit “glucose-addiction”. In our 
model, this was attenuated by ERα knockdown because 
the proliferation of shERα cells was less affected by 
glucose withdrawal than shCtrl cells. The corollary is that 
PTEN-deficient prostate cancer cells expressing ERα are 
reliant on abundant glucose for their rapid proliferation.
In conclusion, we demonstrate that when ERα 
is expressed in prostate cancer cells it regulates 
proliferation, MYC expression and glucose sensitivity. 
The balance between glycolysis and OXPHOS in cancer 
cells has emerged as a major determinant of sensitivity 
to antidiabetic biguanides [41]. This is potentially all the 
more important considering that men taking metformin 
showed reduced prostate cancer specific mortality 
[48]. Further work will be required to determine the 
contribution of classical genomic and rapid non-genomic 
ERα activities, and the specific contributions of ERα 
isoforms (66 and 46kDa splice variants), in regulating 
energy metabolism. 
METHODS
Patient Specimens
Samples of formalin-fixed and paraffin embedded 
human prostate tissue, from 36 patients that had undergone 
radical prostatectomy, were obtained from the Australian 
Prostate Cancer BioResource with human ethics approval 
from ethics committees at Epworth Hospital (35906), 
Cabrini Hospital (10-13-12-04) and Monash University 
(2005-442). An experienced Uropathologist (J.P.) 
determined the Gleason Score and percentage of tumor 
cells expressing ERα in each specimen. Positive ERα 
staining of tumor cells was defined as prominent nuclear 
immunoreactivity compared to negative ERα staining in 
nearby benign glands.
Animals
ARR2/Pbsn-Myc (Hi-MYC) mice were obtained 
from NCI-Frederick, VA, USA and housed and humanely 
killed according to Monash University animal ethics 
approval. The lateral prostate was harvested from 32 
week old Hi-MYC mouse or age-matched control mice. 
PBi-Cre transgenic mice [49] were crossed with Pten 
floxed animals [50] to specifically deplete Pten within the 
prostate epithelium. Animals were maintained on a mixed 
129:fvb/n background. Pten-deficient (PBiCre+/-;Ptenfl/fl) 
and control mice (PBiCre+/-) were used at 80-100 d of age 
for all studies. Experiments were performed according to 
animal ethics approval from the Peter MacCallum Cancer 
Centre.
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Immunohistochemistry
Immunohistochemistry was performed manually 
with the DAKO EnVision+ detection system or with 
an autostainer using the Leica BOND-MAX system 
(Leica Microsystems Pty. Ltd.). The concentration and 
specific conditions for each primary antibody are listed 
in Supplementary Table 2. The specificity of the ERα 
antibody has been confirmed by several independent 
laboratories [11, 12, 51].
Stereology
Slides of stained tissues were imaged with an 
Aperio ScanScope digital scanner and viewed using 
ImageScope software (Aperio). The dorsal, lateral and 
ventral lobes were divided into benign and malignant 
foci. Within the anterior prostate, tumor foci were divided 
into peripheral tumor regions, within 50 μm of the stroma, 
and central tumor regions greater than 100 μm from the 
stroma. The percentage of ERα or Ki67 positive cells was 
manually counted in at least 3 fields per region (average 
~10 fields) for 3 mice. Each field contained an average 
of approximately 150 cells. Data is represented as the 
average percentage of positively stained cells in each 
region per mouse. 
Cell Culture 
MCF7 cells were purchase from the American 
Type Culture Collection and cultured in RPMI medium 
containing 5% fetal bovine serum (FBS), 100 IU/ml 
penicillin and 10 µg/ml streptomycin (Invitrogen). An 
epithelial prostate cancer cell line was established from 
an invasive prostate carcinoma harvested from a 407 day 
old male PBiCre+/-;Ptenfl/fl mouse. Briefly, prostate tumor 
sections approximately 5 mm3 were placed on ice for 1 hr 
in PBS supplemented with 3% penicillin streptomyocin 
(Pen Strep, Gibco) prior to homogenization. Samples 
were then transferred to a T25 flask with 5 ml of α-MEM 
medium containing 20% FBS, 1% soduim pyruvate, 80 
µg/ml Fluconazole, 1% Pen Strep and 1% Glutamate 
(Gibco). Media was replaced every 2-3 days. Cultures 
were then maintained in high glucose DMEM medium 
containing 10% FBS, 100 IU/ml penicillin and 10 µg/
ml streptomycin (Invitrogen) and kept in a humidified 
incubator at 37°C with 5% CO2.
Estrogen antagonist treatments
PTEN-deficient prostate cancer cells were seeded in 
6 well plates (2 x 104/well) and cultured for 24 h. Cells 
were then treated daily for 4 days with media containing 
DMSO or 1 µM TPSF (p-fluoro-4-(1,2,3,6,-tetrahydro-
1,3-dimethyl-2-oxo-6-thionpurin-8-ylthio). On the fifth 
day, cells were trypsinized, resuspended in media and 
counted using a TC10 automated cell counter (BioRad). 
The experiment was performed three times in triplicate.
ERα Knockdown
Knockdown experiments were performed using 
the pGIPZ vector (Open Biosystems) containing either 
a non-silencing control shRNA or a mouse ERα shRNA 
(V2LMM_30677). Viral stocks were prepared from 293-
T cells using the Trans-Lentiviral shRNA Packaging kit 
according to the manufacturer’s instructions. PTEN-
deficient cells were transduced, sorted for GFP expression 
and then maintained in medium supplemented with 4 µg/
mL puromycin.
Proliferation Assays
To assess proliferation, 2 x 104 cells were seeded per 
well in 6-well plates and cultured for 1, 3 or 5 days before 
being trypsinized and counted using a TC10 automated 
cell counter (BioRad). For all cell counts, trypan blue 
was used to measure cell viability, which was typically 
between 97-100% and was not affected by any treatment. 
Therefore, all data are reported as numbers of viable cells. 
Cumulative differences in proliferation were measured 
by seeding, counting and re-seeding 5 x 104 cells every 
4 days for 5 passages. The proliferation of cells in three 
dimensional conditions was measured by seeding 3000 
cells in 100 µL of a 2:3 mixture of media to growth factor-
reduced Matrigel (BD Biosciences). The solution was set 
around the edge of the wells of a 12-well plate and the 
cells were cultured for 10 days. The number of colonies 
was counted with a phase contrast microscope at 20 times 
magnification. The size of colonies was measured using 
ImageJ with images taken at 4 positions per well, typically 
containing a total of 20-30 colonies.
ERα Rescue
To rescue full length ERα expression, 1 x 105 PTEN-
deficient cells were seeded per well in 6 well plates for 
24 hr and then transfected with 2.5 μg of a human ERα66 
construct (pSG5-HEGO) or empty vector control using 
12.5 μl/well of lipofectamine 2000. Cells were harvested 
after 72 hrs. 
Western blotting
Samples were lysed in RIPA buffer containing 5 mM 
NaF, 1 mM Na3VO4 and 1x complete protease inhibitor 
cocktail (Roche) and quantified using the bicinchoninic 
acid assay (Promega). Lysates were separated using 
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polyacrylamide gel electrophoresis and probed with 
primary antibodies listed in Supplementary Table 1. 
Membranes were then incubated with HRP-conjugated 
secondary antibodies (goat anti-rabbit, goat anti-mouse 
(Dako), goat anti-rat (Cell Signaling)) followed by ECL 
Plus Western Blotting Detection Reagent (GE Healthcare).
Microarrays
Cells were lysed in hypotonic lysis buffer (5 mM 
Tris-HCl [pH7.5], 2.5 mM MgCl2, 1.5 mM KCl, 100 μg/
ml cycloheximide, 2 mM DTT, 0.5% Triton X-100, and 
0.5% sodium deoxycholate), supernatant was cleared by 
centrifugation and total RNA was isolated using TRIzol 
Reagent (Life Technologies). RNA from biological 
triplicate experiments were labelled according to the 
manufacturer’s guidelines (Affymetrix), hybridized to 
the Affymetrix Gene ST 1.1 Gene Titan array and 
scanned using the Affymetrix GeneTitan scanner. The 
resulting .CEL files were normalized using updated probe 
set definitions [52], because these provide improved 
precision and accuracy as compared to the default probe 
set definitions [53], and the robust multi-array average 
(RMA) algorithm [54] using the “affy” R (r-project.org) 
package. Differential expression was identified using the 
random variance model t-statistics [55] and the resulting 
p-values were adjusted using the Benjamini-Hochberg 
False Discovery Rate (FDR) method [56]. Genes with an 
FDR<0.1 and a fold-change >log2(1.5) were considered 
significantly differentially expressed. To identify functions 
enriched among genes at the ends of a gene list ranked 
by signed (up[+] or down[-]) –log10(p-values), we used 
GAGE [57] and annotations from the gene ontology 
consortium [58]. Within the “gage” function we used rank.
test=TRUE and default settings (i.e. categories containing 
between 10 and 500 genes were considered). Categories 
with an FDR<0.1 were considered significant enriched.
Glucose Deprivation
Cells were seeded at 2 x 104 cells per well in 6 well 
plates in standard high glucose (25 mM) DMEM medium 
containing 10% FBS, 100 IU/ml penicillin and 10 µg/ml 
streptomycin (Invitrogen). After 24 hr, the medium was 
changed to standard high glucose medium or glucose-
free DMEM, both containing 10% FBS and antibiotics. 
After 3 days, the cells were trypsinized and counted using 
an automated cell counter. Data was normalized to the 
average number of cells in high glucose medium. The 
experiment was repeated 4 times in triplicate.
RNA extraction and quantitative RT-PCR
Total RNA was extracted using an RNeasy 
kit (Qiagen) and treated with DNase I according to 
the manufacturer’s instructions (Life Technologies). 
Complementary DNA was synthesized using the 
SuperScript III First Strand Synthesis System (Life 
Technologies). Samples were amplified using Power Sybr 
Green (Life Technologies) and gene-specific primers 
(Sigma Aldrich; Supplementary Table 3) on an ABI7900 
thermocycler (Life Technologies). Target genes were 
normalized to the geometric mean of three reference 
genes, RPLP0, HPRT1 and UBC. Relative gene expression 
was calculated using the delta delta Ct method.
Statistical Analyses
GraphPad Prism software was used to generate 
graphs and perform statistical analyses, which are noted in 
figure legends. All data are displayed with standard error 
of the mean calculated from independent experiments.
ACKNOWLEDGEMENTS
We gratefully acknowledge the expert assistance of 
Birunthi Niranjan, Michelle Richards, Shelley Hedwards 
and Melissa Papargiris. 
Financial Support 
Funding was obtained from the National Health 
and Medical Research Council (Enabling Grant to 
APCB: 614296, Fellowship to GR: 1002648, Project 
Grant: 1020959, Fellowship to ML: 1035721, Fellowship 
to MW: 606460), Prostate Cancer Foundation of 
Australia (Infrastructure grant to APCB; Movember 
Young Investigator Grants to RT, ML, LF and HP) and 
Australian Research Council (DECRA Fellowship to LF: 
DE120100434). EG supported by MICRTP Studentship. 
OL is funded by the Swedish Research Council, the 
Swedish Cancer Foundation and the Wallenberg Academy 
Fellows program. HP is supported by a Richard Pratt 
Foundation Fellowship for Prostate Cancer Research.
Conflicts of Interest
The authors do not have any conflicts of interest to 
report.
REFERENCES
1. Siegel R, Ma J, Zou Z and Jemal A. Cancer statistics, 2014. 
CA Cancer J Clin. 2014; 64(1):9-29.
Oncotarget614www.impactjournals.com/oncotarget
2. Travison TG, Araujo AB, Kupelian V, O’Donnell AB and 
McKinlay JB. The relative contributions of aging, health, 
and lifestyle factors to serum testosterone decline in men. J 
Clin Endocrinol Metab. 2007; 92(2):549-555.
3. Risbridger GP, Davis ID, Birrell SN and Tilley W. Breast 
and prostate cancer: more similar than different. Nature 
Review Cancer. 2010; 10(3):205-212.
4. Ricke WA, McPherson SJ, Bianco JJ, Cunha GR, Wang 
Y and Risbridger GP. Prostatic hormonal carcinogenesis 
is mediated by in situ estrogen production and estrogen 
receptor alpha signaling. FASEB J. 2008; 22(5):1512-1520.
5. Wang Y, Sudilovsky D, Zhang B, Haughney PC, Rosen 
MA, Wu DS, Cunha TJ, Dahiya R, Cunha GR and Hayward 
SW. A human prostatic epithelial model of hormonal 
carcinogenesis. Cancer Res. 2001; 61(16):6064-6072.
6. Ellem SJ and Risbridger GP. Treating prostate cancer: a 
rationale for targeting local oestrogens. Nat Rev Cancer. 
2007; 7(8):621-627.
7. Sugiyama N, Barros RP, Warner M and Gustafsson JA. 
ERbeta: recent understanding of estrogen signaling. Trends 
Endocrinol Metab. 2010; 21(9):545-552.
8. Hussain S, Lawrence MG, Taylor RA, Lo CY, Frydenberg 
M, Ellem SJ, Furic L and Risbridger GP. Estrogen receptor 
beta activation impairs prostatic regeneration by inducing 
apoptosis in murine and human stem/progenitor enriched 
cell populations. PLoS ONE. 2012; 7(7):e40732.
9. McPherson SJ, Hussain S, Balanathan P, Hedwards SL, 
Niranjan B, Grant M, Chandrasiri UP, Toivanen R, Wang 
Y, Taylor RA and Risbridger GP. Estrogen receptor-beta 
activated apoptosis in benign hyperplasia and cancer of the 
prostate is androgen independent and TNFalpha mediated. 
Proc Natl Acad Sci U S A. 2010; 107(7):3123-3128.
10. Mak P, Leav I, Pursell B, Bae D, Yang X, Taglienti CA, 
Gouvin LM, Sharma VM and Mercurio AM. ERbeta 
impedes prostate cancer EMT by destabilizing HIF-1alpha 
and inhibiting VEGF-mediated snail nuclear localization: 
implications for Gleason grading. Cancer Cell. 2010; 
17(4):319-332.
11. Bonkhoff H, Fixemer T, Hunsicker I and Remberger 
K. Estrogen receptor expression in prostate cancer and 
premalignant prostatic lesions. Am J Pathol. 1999; 
155(2):641-647.
12. Leav I, Lau, K. M, Adams, J. Y, McNeal, J. E, Taplin, M. 
E, Wang, J, Singh, H, Ho, S. M. Comparative studies of the 
estrogen receptors beta and alpha and the androgen receptor 
in normal human prostate glands, dysplasia, and in primary 
and metastatic carcinoma. Am J Pathol. 2001; 159(1):79-92.
13. Royuela M, de Miguel MP, Bethencourt FR, Sanchez-
Chapado M, Fraile B, Arenas MI and Paniagua R. Estrogen 
receptors alpha and beta in the normal, hyperplastic 
and carcinomatous human prostate. J Endocrinol. 2001; 
168(3):447-454.
14. Hobisch A, Hittmair A, Daxenbichler G, Wille S, Radmayr 
C, Hobisch-Hagen P, Bartsch G, Klocker H and Culig Z. 
Metastatic lesions from prostate cancer do not express 
oestrogen and progesterone receptors. J Pathol. 1997; 
182(3):356-361.
15. Celhay O, Yacoub M, Irani J, Dore B, Cussenot O and 
Fromont G. Expression of estrogen related proteins in 
hormone refractory prostate cancer: association with tumor 
progression. J Urol. 2010; 184(5):2172-2178.
16. Hetzl AC, Montico F, Lorencini RM, Kido L, Candido E, 
Billis A, Ferreira U and Cagnon VH. Fibroblast growth 
factor, estrogen, and prolactin receptor features in different 
grades of prostatic adenocarcinoma in elderly men. Microsc 
Res Tech. 2013; 76(3):321-330.
17. Megas G, Chrisofos M, Anastasiou I, Tsitlidou A, 
Choreftaki T and Deliveliotis C. Estrogen receptor 
(alpha and beta) but not androgen receptor expression is 
correlated with recurrence, progression and survival in post 
prostatectomy T3N0M0 locally advanced prostate cancer in 
an urban Greek population. Asian J Androl. 2014.
18. Linja MJ, Savinainen KJ, Tammela TL, Isola JJ and 
Visakorpi T. Expression of ERalpha and ERbeta in prostate 
cancer. Prostate. 2003; 55(3):180-186.
19. Sasaki M, Tanaka Y, Perinchery G, Dharia A, Kotcherguina 
I, Fujimoto S and Dahiya R. Methylation and inactivation of 
estrogen, progesterone, and androgen receptors in prostate 
cancer. J Natl Cancer Inst. 2002; 94(5):384-390.
20. Li LC, Chui R, Nakajima K, Oh BR, Au HC and Dahiya 
R. Frequent methylation of estrogen receptor in prostate 
cancer: correlation with tumor progression. Cancer Res. 
2000; 60(3):702-706.
21. Lau KM, LaSpina M, Long J and Ho SM. Expression 
of estrogen receptor (ER)-alpha and ER-beta in normal 
and malignant prostatic epithelial cells: regulation by 
methylation and involvement in growth regulation. Cancer 
Res. 2000; 60(12):3175-3182.
22. Setlur SR, Mertz KD, Hoshida Y, Demichelis F, Lupien 
M, Perner S, Sboner A, Pawitan Y, Andren O, Johnson 
LA, Tang J, Adami HO, Calza S, Chinnaiyan AM, Rhodes 
D, Tomlins S, et al. Estrogen-dependent signaling in a 
molecularly distinct subclass of aggressive prostate cancer. 
J Natl Cancer Inst. 2008; 100(11):815-825.
23. McDevitt MA, Glidewell-Kenney C, Jimenez MA, Ahearn 
PC, Weiss J, Jameson JL and Levine JE. New insights into 
the classical and non-classical actions of estrogen: evidence 
from estrogen receptor knock-out and knock-in mice. Mol 
Cell Endocrinol. 2008; 290(1-2):24-30.
24. Parsons S, Pritchard J, Fox E and Shupnik M. (2012). 
Cooperative Interactions Between c-Src, Estrogen 
Receptors and Receptor Tyrosine Kinases in Breast Cancer. 
In: Castoria G and Migliaccio A, eds. Advances in Rapid 
Sex-Steroid Action: Springer New York), pp. 31-59.
25. Pandini G, Genua M, Frasca F, Squatrito S, Vigneri R and 
Belfiore A. 17beta-estradiol up-regulates the insulin-like 
growth factor receptor through a nongenotropic pathway in 
prostate cancer cells. Cancer Res. 2007; 67(18):8932-8941.
Oncotarget615www.impactjournals.com/oncotarget
26. Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin 
WW and Liao JK. Interaction of oestrogen receptor with 
the regulatory subunit of phosphatidylinositol-3-OH kinase. 
Nature. 2000; 407(6803):538-541.
27. Shupnik MA. Crosstalk between steroid receptors and the 
c-Src-receptor tyrosine kinase pathways: implications for 
cell proliferation. Oncogene. 2004; 23(48):7979-7989.
28. Phin S, Moore MW and Cotter PD. Genomic 
Rearrangements of PTEN in Prostate Cancer. Front Oncol. 
2013; 3:240.
29. Sircar K, Yoshimoto M, Monzon FA, Koumakpayi IH, Katz 
RL, Khanna A, Alvarez K, Chen G, Darnel AD, Aprikian 
AG, Saad F, Bismar TA and Squire JA. PTEN genomic 
deletion is associated with p-Akt and AR signalling in 
poorer outcome, hormone refractory prostate cancer. J 
Pathol. 2009; 218(4):505-513.
30. Wang J, Kobayashi T, Floc’h N, Kinkade CW, Aytes 
A, Dankort D, Lefebvre C, Mitrofanova A, Cardiff RD, 
McMahon M, Califano A, Shen MM and Abate-Shen C. 
B-Raf activation cooperates with PTEN loss to drive c-Myc 
expression in advanced prostate cancer. Cancer Res. 2012; 
72(18):4765-4776.
31. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki 
M, Koutcher JA, Scher HI, Ludwig T, Gerald W, Cordon-
Cardo C and Pandolfi PP. Crucial role of p53-dependent 
cellular senescence in suppression of Pten-deficient 
tumorigenesis. Nature. 2005; 436(7051):725-730.
32. Kim J, Roh M, Doubinskaia I, Algarroba GN, Eltoum IE 
and Abdulkadir SA. A mouse model of heterogeneous, 
c-MYC-initiated prostate cancer with loss of Pten and p53. 
Oncogene. 2012; 31(3):322-332.
33. Wang S, Garcia AJ, Wu M, Lawson DA, Witte ON and Wu 
H. Pten deletion leads to the expansion of a prostatic stem/
progenitor cell subpopulation and tumor initiation. Proc 
Natl Acad Sci U S A. 2006; 103(5):1480-1485.
34. Kretzer NM, Cherian MT, Mao C, Aninye IO, Reynolds 
PD, Schiff R, Hergenrother PJ, Nordeen SK, Wilson 
EM and Shapiro DJ. A noncompetitive small molecule 
inhibitor of estrogen-regulated gene expression and breast 
cancer cell growth that enhances proteasome-dependent 
degradation of estrogen receptor {alpha}. J Biol Chem. 
2010; 285(53):41863-41873.
35. Mulholland DJ, Xin L, Morim A, Lawson D, Witte O and 
Wu H. Lin-Sca-1+CD49fhigh stem/progenitors are tumor-
initiating cells in the Pten-null prostate cancer model. 
Cancer Res. 2009; 69(22):8555-8562.
36. Lin CJ, Malina A and Pelletier J. c-Myc and eIF4F 
constitute a feedforward loop that regulates cell growth: 
implications for anticancer therapy. Cancer Res. 2009; 
69(19):7491-7494.
37. Krum SA, Miranda-Carboni GA, Lupien M, Eeckhoute J, 
Carroll JS and Brown M. Unique ERalpha cistromes control 
cell type-specific gene regulation. Mol Endocrinol. 2008; 
22(11):2393-2406.
38. Kalaany NY and Sabatini DM. Tumours with PI3K 
activation are resistant to dietary restriction. Nature. 2009; 
458(7239):725-731.
39. Blouin MJ, Zhao Y, Zakikhani M, Algire C, Piura E and 
Pollak M. Loss of function of PTEN alters the relationship 
between glucose concentration and cell proliferation, 
increases glycolysis, and sensitizes cells to 2-deoxyglucose. 
Cancer Lett. 2010; 289(2):246-253.
40. O’Mahony F, Razandi M, Pedram A, Harvey BJ and Levin 
ER. Estrogen modulates metabolic pathway adaptation to 
available glucose in breast cancer cells. Mol Endocrinol. 
2012; 26(12):2058-2070.
41. Birsoy K, Possemato R, Lorbeer FK, Bayraktar EC, Thiru P, 
Yucel B, Wang T, Chen WW, Clish CB and Sabatini DM. 
Metabolic determinants of cancer cell sensitivity to glucose 
limitation and biguanides. Nature. 2014; 508(7494):108-
112.
42. Tai S, Sun Y, Squires JM, Zhang H, Oh WK, Liang CZ and 
Huang J. PC3 is a cell line characteristic of prostatic small 
cell carcinoma. Prostate. 2011; 71(15):1668-1679.
43. Mertz KD, Setlur SR, Dhanasekaran SM, Demichelis F, 
Perner S, Tomlins S, Tchinda J, Laxman B, Vessella RL, 
Beroukhim R, Lee C, Chinnaiyan AM and Rubin MA. 
Molecular characterization of TMPRSS2-ERG gene fusion 
in the NCI-H660 prostate cancer cell line: a new perspective 
for an old model. Neoplasia. 2007; 9(3):200-206.
44. Fisher G, Yang ZH, Kudahetti S, Moller H, Scardino 
P, Cuzick J, Berney DM and Transatlantic Prostate G. 
Prognostic value of Ki-67 for prostate cancer death in 
a conservatively managed cohort. Br J Cancer. 2013; 
108(2):271-277.
45. Shtivelman E, Beer TM and Evans CP. Molecular 
pathways and targets in prostate cancer. Oncotarget. 2014; 
5(17):7217-7259.
46. Cho NY, Choi M, Kim BH, Cho YM, Moon KC and 
Kang GH. BRAF and KRAS mutations in prostatic 
adenocarcinoma. Int J Cancer. 2006; 119(8):1858-1862.
47. Kollermann J, Albrecht H, Schlomm T, Huland H, Graefen 
M, Bokemeyer C, Simon R, Sauter G and Wilczak W. 
Activating BRAF gene mutations are uncommon in 
hormone refractory prostate cancer in Caucasian patients. 
Oncol Lett. 2010; 1(4):729-732.
48. Margel D, Urbach DR, Lipscombe LL, Bell CM, Kulkarni 
G, Austin PC and Fleshner N. Metformin use and all-cause 
and prostate cancer-specific mortality among men with 
diabetes. J Clin Oncol. 2013; 31(25):3069-3075.
49. Jin C, McKeehan K and Wang F. Transgenic mouse with 
high Cre recombinase activity in all prostate lobes, seminal 
vesicle, and ductus deferens. Prostate. 2003; 57(2):160-164.
50. Lesche R, Groszer M, Gao J, Wang Y, Messing A, Sun 
H, Liu X and Wu H. Cre/loxP-mediated inactivation of 
the murine Pten tumor suppressor gene. Genesis. 2002; 
32(2):148-149.
51. Bevitt DJ, Milton ID, Piggot N, Henry L, Carter MJ, 
Oncotarget616www.impactjournals.com/oncotarget
Toms GL, Lennard TW, Westley B, Angus B and 
Horne CH. New monoclonal antibodies to oestrogen 
and progesterone receptors effective for paraffin section 
immunohistochemistry. J Pathol. 1997; 183(2):228-232.
52. Dai M, Wang P, Boyd AD, Kostov G, Athey B, Jones EG, 
Bunney WE, Myers RM, Speed TP, Akil H, Watson SJ and 
Meng F. Evolving gene/transcript definitions significantly 
alter the interpretation of GeneChip data. Nucleic Acids 
Res. 2005; 33(20):e175.
53. Sandberg R and Larsson O. Improved precision and 
accuracy for microarrays using updated probe set 
definitions. BMC Bioinformatics. 2007; 8:48.
54. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, 
Antonellis KJ, Scherf U and Speed TP. Exploration, 
normalization, and summaries of high density 
oligonucleotide array probe level data. Biostatistics. 2003; 
4(2):249-264.
55. Wright GW and Simon RM. A random variance model for 
detection of differential gene expression in small microarray 
experiments. Bioinformatics. 2003; 19(18):2448-2455.
56. Benjamini Y and Hochberg Y. Controlling the False 
Discovery Rate: A Practical and Powerful Approach to 
Multiple Testing. Journal of the Royal Statistical Society 
Series B (Methodological. 1995; 57(1):289-300.
57. Luo W, Friedman MS, Shedden K, Hankenson KD and 
Woolf PJ. GAGE: generally applicable gene set enrichment 
for pathway analysis. BMC Bioinformatics. 2009; 10:161.
58. Gene Ontology C, Blake JA, Dolan M, Drabkin H, Hill DP, 
Li N, Sitnikov D, Bridges S, Burgess S, Buza T, McCarthy 
F, Peddinti D, Pillai L, Carbon S, Dietze H, Ireland A, et al. 
Gene Ontology annotations and resources. Nucleic Acids 
Res. 2013; 41(Database issue):D530-535.
